Role of Natural Autoantibodies and Natural IgM Anti-Leucocyte Autoantibodies in Health and Disease by Peter Isaac Lobo
June 2016 | Volume 7 | Article 1981
Review
published: 06 June 2016
doi: 10.3389/fimmu.2016.00198
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Nichol E. Holodick, 
The Feinstein Institute for Medical 
Research, USA
Reviewed by: 
Ziaur S. M. Rahman, 
Pennsylvania State University, USA 
Christoph J. Binder, 
Medical University of Vienna, Austria
*Correspondence:
Peter Isaac Lobo  
pil@virginia.edu
Specialty section: 
This article was submitted to 
B Cell Biology, 






Lobo PI (2016) Role of Natural 
Autoantibodies and Natural IgM 
Anti-Leucocyte Autoantibodies in 
Health and Disease. 
Front. Immunol. 7:198. 
doi: 10.3389/fimmu.2016.00198
Role of Natural Autoantibodies and 
Natural igM Anti-Leucocyte 
Autoantibodies in Health and Disease
Peter Isaac Lobo*
Department of Internal Medicine, Division of Nephrology, Center of Immunology, Inflammation and Regenerative Medicine, 
University of Virginia Health Center, Charlottesville, VA, USA
We review how polyreactive natural IgM autoantibodies (IgM-NAA) protect the host from 
invading micro-organisms and host neo-antigens that are constantly being produced 
by oxidation mechanisms and cell apoptosis. Second, we discuss how IgM-NAA and 
IgM anti-leukocyte antibodies (IgM-ALA) inhibits autoimmune inflammation by anti- 
idiotypic mechanisms, enhancing removal of apoptotic cells, masking neo-antigens, and 
regulating the function of dendritic cells (DC) and effector cells. Third, we review how 
natural IgM prevents autoimmune disorders arising from pathogenic IgG autoantibodies, 
triggered by genetic mechanisms (e.g., SLE) or micro-organisms, as well as by autore-
active B and T cells that have escaped tolerance mechanisms. Studies in IgM knockout 
mice have clearly demonstrated that regulatory B and T cells require IgM to effectively 
regulate inflammation mediated by innate, adaptive, and autoimmune mechanisms. It is, 
therefore, not surprising why the host positively selects such autoreactive B1 cells that 
generate IgM-NAA, which are also evolutionarily conserved. Fourth, we show that IgM-
ALA levels and their repertoire can vary in normal humans and disease states and this 
variation may partly explain the observed differences in the inflammatory response after 
infection, ischemic injury, or after a transplant. We also show how protective IgM-NAA 
can be rendered pathogenic under non-physiological conditions. We also review IgG-
NAA that are more abundant than IgM-NAA in plasma. However, we need to understand 
if the (Fab)2 region of IgG-NAA has physiological relevance in non-disease states, as 
in plasma, their functional activity is blocked by IgM-NAA having anti-idiotypic activity. 
Some IgG-NAA are produced by B2 cells that have escaped tolerance mechanisms and 
we show how such pathogenic IgG-NAA are regulated to prevent autoimmune disease. 
The Fc region of IgG-NAA can influence inflammation and B cell function in  vivo by 
binding to activating and inhibitory FcγR. IgM-NAA has therapeutic potential. Polyclonal 
IgM infusions can be used to abrogate on-going inflammation. Additionally, inflammation 
arising after ischemic kidney injury, e.g., during high-risk elective cardiac surgery or after 
allograft transplantation, can be prevented by pre-emptively infusing polyclonal IgM or 
DC pretreated ex vivo with IgM or by increasing in vivo IgM with a vaccine approach. Cell 
therapy is appealing as less IgM will be required.
Keywords: natural igG autoantibodies, natural igM autoantibodies, natural autoantibodies, natural igM anti-
leukocyte antibodies, allograft rejection, TH-17, renal iRi, autoimmune insulitis, regulation of co-stimulatory 
receptors, regulatory dendritic cells
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iNTRODUCTiON
The study of natural IgM autoantibodies (IgM-NAA) has given 
us a good insight on how nature, by creating polyreactive pen-
tavalent antibodies, has accomplished a difficult task of trying to 
protect the host from both diverse foreign pathogens and from 
diverse self neo-antigens that are constantly produced within 
the host. Poly-reactivity with low binding affinity, but with high 
avidity, has enabled these IgM-NAA-producing B cell clones to be 
rapidly activated by a foreign or an auto neo-antigen for deploy-
ing protective mechanisms to the host. Such a response provides 
time for the adaptive immune system to mount a highly specific 
immune response to foreign antigens and, in addition, lessens the 
burden on the host to maintain diverse B cell clones producing 
highly specific IgG auto-antibodies, which has the potential of 
causing autoimmune disease owing to their high-affinity binding. 
Second, since both foreign and self neo-antigens can induce an 
inflammatory response, these IgM-NAA have taken over another 
task of subduing an excessive inflammatory response that can 
injure the host. This regulation of inflammatory cells without 
damage is made possible by the low binding affinity of IgM-
ALA to live leukocytes, combined with its inability to effectively 
activate the lytic component of complement at body temperature 
(37°C). Hence, it is not surprising why these IgM-NAA antibod-
ies, which first arose in cartilaginous fish, have been conserved 
during evolution [reviewed in Ref. (1)] and why IgM-NAA makes 
up about 70–80% of circulating IgM (2, 3). Additionally, some 
studies have shown that the binding of natural IgM to autologous 
receptors is also evolutionarily conserved among mammalian 
species as human IgM has the same functional effect as murine 
IgM on murine cells in vitro or when used in vivo in mice (4–6).
Natural autoantibodies of different isotypes have been inten-
sively studied during the last 40 years (7–17). These autoantibod-
ies have been termed “natural antibodies” as they are produced 
at birth in the absence of exposure to foreign antigens. The full 
repertoire of NAA develops by early childhood. In mice, NAA are 
predominantly produced by the CD5+ B1 cells, while marginal-
zone splenic B (MZB) cells contribute the remainder. These B1 
cells produce predominantly IgM, IgA, and IgG3 autoantibodies 
(18, 19), independently of T cell help, and exhibit an enhanced 
response to innate immune signals, such as TLR agonist. Hence, 
B1 and MZB cells differ from B2 cells in that the response of these 
cells in  vivo is rapid and can be driven by TLR agonists inde-
pendently of antigen binding to their BCR (20–23). Additionally, 
there are data to indicate that autoantibody-producing B1 cells, 
unlike self-reactive T cells, are positively selected for their self-
reactivity, thus implying that NAA are conserved by design 
(24–27). Further support for their importance comes from stud-
ies in chimeric mice demonstrating that IgM-NAA comprise the 
majority of circulating IgM (2, 3). Most cross-sectional studies in 
humans and rodents would indicate that IgM-NAA decrease with 
age (28–31) or lose their effectiveness with age (32) except for one 
report where follow-up of five healthy individuals for 25  years 
revealed no change in IgM-NAA levels (33). However, IgG-NAA 
can increase (34) but do not decrease with age (35, 36).
Innately produced natural IgM-NAA should not be confused 
with immune IgM and IgG that are produced several days later 
after exposure to foreign antigens or pathogens. Such immune 
IgM and IgG are not natural autoantibodies and in general are 
antigen specific and are produced by B2 cells that require antigen 
binding to BcR and additional T cell help to generate anti-protein 
antibodies. However, production of immune IgM is limited as 
these IgM secreting B2 cells migrate to B cell follicles, where with 
the help of T cells, these B2 cells undergo isotype switching and 
somatic hyper-mutation, thus generating long-lived memory 
B cells and differentiating into plasma cells that produce IgG 
antibodies with high-affinity binding.
The human equivalent of the murine CD5+ B1 subset has 
been recently identified and characterized. This CD20+ CD43+ 
CD27+ human B1 subset that can spontaneously secrete antibody 
represents about 50% of umbilical cord B cells and 15–20% of 
circulating adult B cells, and is the predominant source of human 
IgM-NAA (29). In humans, CD5 is not a specific marker of B1 as 
this marker is expressed by both B1 and B2 cells. Similarly, CD43 
and CD27 are not specific markers for human B1 as about 20% of 
CD43+ CD 27+ B cells have characteristics of pre-plasmablasts 
that are derived from T-dependent B cells present in germinal 
centers (37, 38). Human IgM-NAA are also polyreactive and 
bind similar autoantigens as in mice, including oxidized neo-
determinants and leukocyte receptors (4, 39–41).
igM-NAA, igG-NAA, and Pathogenic 
igG Autoantibodies
One physiological role of NAA is to protect the host from patho-
genic IgG autoantibodies. We will, therefore, briefly describe 
the biology of natural IgM and IgG-NAA and pathogenic IgG 
autoantibodies in health and disease and then discuss the dif-
ferent mechanisms used by NAA to counter pathogenic IgG. B1 
cells have been shown to secrete IgM, IgA, and IgG3-NAA that 
are encoded by minimally or non-mutated germ line genes that 
are enriched for heavy chain variable region rearrangements and 
with H-L pairings that allow for poly-reactivity (18, 19). NAA 
generated by B1 cells rarely undergo isotype switching or somatic 
hyper-mutation to acquire antigen specificity. IgA in the gut is 
predominantly produced by B1 cells present in the gut lymphoid 
tissue but there is increasing evidence to show that B2 cells can 
also participate in gut mucosal immunity and this could account 
for the observed somatic hyper-mutation and antigen specificity 
of gut mucosal IgA (42–46).
Natural IgM Autoantibodies
In mice, the majority of IgM-NAA are produced by splenic B1 and 
MZB cells (47–49). B1 and MZB cells, such as memory B cells, 
express CD27 and spontaneously produce IgM, but IgM produc-
tion can also be increased by TLR activation [e.g., lipopolysac-
charide (LPS)] or via the BCR in response to pathogens. Normal 
levels of IgM-NAA are present at birth even under germ-free con-
ditions and in nude mice, indicating that IgM-NAA production 
is not dependent on exposure to foreign antigens, TLR or T cell 
activation (50). IgM-NAA repertoire is shaped by T-independent 
antigen activation, especially of MZB cells (51, 52). An important 
characteristic of these antibodies is their low binding affinity (53). 
It is possible that the membrane expressed IgM or BCR of B1 and 
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MZB cells producing NAA also exhibit low binding affinity and 
perhaps this latter characteristic may be involved in preventing 
autoreactive B1 cells from being deleted or undergoing negative 
selection. There are data to show that autoreactive B1 cells are 
positively selected and this process requires both the autoantigen 
and the relevant BCR (24–27). The need to positively select B1 
cells secreting IgM-NAA would indicate that these antibodies 
have an important physiological role that will be reviewed later.
Natural IgM autoantibodies have been shown to be polyclonal 
with clones having specificity for some, but not all self-antigens, i.e., 
certain common epitopes present on phylogenetically conserved 
self-antigens. Some of these IgM clones with reactivity to self-
antigens have been identified, e.g., IgM clones with specificity for 
leukocyte receptors [IgM anti-leukocyte antibodies (IgM-ALA)] 
(4, 39), Fc domain of IgG (rheumatoid factor) (14, 15), comple-
ment components (17), collagen, thyroglobulin, intracellular con-
stituents, such as cytoskeletal proteins, cytosolic enzymes, dsDNA, 
or nucleosomes, neutrophil cytoplasmic enzymes (ANCA) (50, 
54) and oxidized neo-determinants [e.g., phosphorylcholine 
(PC)] that are exposed when lipids are oxidized or cells undergo 
apoptosis (55, 56). While some IgM-ALA have mono-reactivity, 
e.g., to some cytokines, most are polyreactive with each polyreac-
tive IgM-NAA clone having a selective binding profile (50). For 
example, IgM anti-PC NAA will bind to ABO blood type antigens, 
endotoxins, and oxidized neo-determinants on apoptotic cells but 
this autoantibody has no binding reactivity to nuclear antigens 
or to IgG (57). Additionally, these IgM-NAA, by virtue of being 
polyreactive, also cross-react with pathogen-expressed molecules, 
for example, PC on Streptococcus pneumoniae and other antigens 
expressed by various viruses and parasites (55–57) Hence, it has 
been suggested that these natural IgM antibodies are protective, 
serving as a first line of defense against infections and protecting 
the host from pathogen-mediated apoptotic cells and oxidized 
neo-determinants that can induce pathogenic IgG autoantibodies 
(55, 56). Additionally, polyreactive IgM-NAA have been shown to 
bind to idiotypic determinants on self-reactive IgG, thus providing 
another mechanism to protect the host from high-affinity binding 
IgG autoantibodies that are potentially pathogenic (31, 50).
In mice, B1 cells are rare in the bone-marrow, lymph nodes, 
and splenic B cell follicles (white pulp) while significant numbers 
of B1 cells are located in the splenic marginal zone as well as in the 
peritoneal and pleural cavities. However, under normal conditions, 
these peritoneal B1 cells do not contribute significantly to circulat-
ing IgM-NAA, but during sepsis, peritoneal B1 cells rapidly migrate 
to the splenic marginal zone (23, 58) where most of the circulating 
IgM-NAA are produced (59). B1 cells are distinct from B2 cells in 
many respects and they are derived from different progenitors (18, 
19, 60). Importantly B1cells express CD27, a memory B cell marker, 
and such as memory B cells, on encountering antigen, spontane-
ously secrete IgM without requiring signaling via co-stimulatory 
molecules (60). B1 cells do not require to traffic or reside in the 
splenic B2/T cell follicles as they are T independent and secrete IgM 
without isotype switching or somatic mutation (25, 59, 61). In fact, 
isotype switching and somatic hyper-mutation of immunoglobulins 
in B1 cells is kept in check during an immune response to prevent 
the development of high affinity, anti-self IgG antibodies (61, 62). In 
this regard, SPA-1 in B-1 cells inhibits Rap-1 GTP, which enhances 
somatic hyper-mutation and hence SPA-1 deficient mice generate 
high-affinity IgG anti-dsDNA and anti-red blood cell autoantibod-
ies and develop lupus nephritis as they age (62). Recent data would 
indicate that levels of peritoneal B1 and splenic B1 and MZB cells is 
regulated by serum levels of polyclonal (but not monoclonal) IgM 
(63–65) that interacts with FcμR expressed by these cells (66) as well 
as by IgG binding to FcγRIIB (67).
IgG-NAA
One can demonstrate the existence of IgG-NAA in normal adult 
murine or human serum under conditions where serum IgM is 
either removed or diluted out (31, 68–70), indicating therefore that 
in serum the functional activity of IgG-NAA is blocked by polyreac-
tive IgM with anti-idiotypic activity (31, 50, 54). There is, however, 
a large amount of IgG-NAA as significant levels of IgG-NAA can 
be detected even after diluting serum at 1:500 (34). Both IgG-NAA 
and IgM-NAA bind to the same phylogenetically conserved self-
antigens and 15–20% of normal mouse IgG has been found to be 
polyreactive (50, 68). IgG produced by B1 cells are characteristically 
of the IgG3 isotype that have been shown to be polyreactive (18, 
19). Clones of B cells secreting IgG4κ with high-affinity binding to 
dsDNA has been shown to exist in human umbilical cord blood and 
in the same umbilical cord there were other B cell clones producing 
IgM antibodies with binding reactivity to idiotypic determinants 
on IgG4 anti-dsDNA but not to idiotypic determinants on other 
IgG4 antibodies (34). The above observations would suggest that 
B cells generating IgG-NAA of different isotypes and affinities are 
present at birth and the IgG-NAA are rendered functionally inactive 
by polyreactive IgM with anti-idiotypic activity.
Importantly, IgG-NAA-producing B cells, unlike IgM-NAA-
producing B cells, are in an inactive state at birth and in mice 
these B cells start producing IgG-NAA after exposure to bowel 
bacteria or foreign antigens (71–73). In humans, it may take more 
than 2 years before significant levels of IgG-NAA can be detected 
in the serum (74). It is also possible that autoreactive T cells, 
which have been shown to exist in normal individuals (75) or 
infectious agents could activate B cells to produce IgG-NAA later 
on in life. For example, levels of polyreactive IgG anti-dsDNA 
have been shown to increase after various infections and these 
polyreactive IgG anti-dsDNA have been found to cross-react 
with antigens on micro-organisms, including bacteria (76). It 
is, therefore, not surprising that low levels of IgG-NAA at birth 
increase after exposure to infections (71–73).
Studies on IgG-NAA isotypes in normal sera or on the B cell 
subsets that produce these antibodies are lacking. There are, 
however, extensive data on an IgG-NAA, i.e., IgG anti-DNA, 
that is both mono-reactive and polyreactive and present in 
both normal sera and SLE sera and some of the findings with 
IgG anti-DNA may apply to other IgG-NAA. Several lines of 
evidence would favor that B2 cells, with the help of T cells, 
can generate IgG-NAA. Wardemann et al. clearly demonstrated 
that 55–75% of early B cell precursors, present in human adult 
bone-marrow, display auto-reactivity to conserved intracel-
lular cytoplasmic and nuclear constituents. About 80% of 
these autoreactive B cells are removed at two check points, 
i.e., centrally in the bone-marrow and in the periphery (77). 
Second, in human umbilical cord, B cells secreting high-affinity 
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binding IgG4 anti-dsDNA have been isolated and IgG1 anti-
myeloperoxidase (ANCA) antibodies have been found in 
normal human sera, indicating that these high-affinity isotype-
switched antibodies are produced by the T cell-dependent B2 
cells (34, 78). Furthermore, in the MLR/lpr murine model of 
SLE, IgG anti-dsDNA has been shown to be produced by B2 
cells under the influence of excess T helper cells as a result of 
Fas deficiency (79). Hence, removing T cells ameliorates SLE 
and reduces production of IgG anti-DNA in this model of SLE 
(80–82).
Under normal conditions, it is unclear whether the (Fab)2 
region of IgG-NAA is physiologically active especially since 
their activity is blocked by poly reactive IgM with anti-idiotypic 
activity (31, 50). Hence, most of the physiological functions 
of IgG-NAA have been derived from purified IgG or pooled 
purified IgG (IVIG). In vivo infusion of IVIG has been shown 
to ameliorate cell-mediated inflammatory processes, e.g., in 
Kawasaki’s disease or autoantibody-mediated disorders, e.g., in 
idiopathic thrombocytopenic purpura, anti-factor VIII autoim-
mune disease, or myasthenia gravis [reviewed in Ref. (83)]. One 
can show, in in vitro studies, that the beneficial effects of purified 
IgG-NAA can be mediated by both the (Fab)2 region and the Fc 
region of IgG-NAA. In these in vitro studies, the (Fab)2 region 
has been shown to (i) block function of activating FcγR receptors 
expressed by monocytes/macrophages. Such activating FcγR 
are involved in phagocytosis of IgG autoantibody complexed 
to platelets, (ii) block idiotypic determinants on IgG autoanti-
bodies, thus neutralizing these antibodies, e.g., their binding 
to Factor VIII or platelets, (iii) inhibit function of certain pro-
inflammatory cytokines by binding to these cytokines or their 
receptors, and (iv) provide protection against bacterial infection 
by binding of IgG-NAA to lectins on bacterial surfaces thus 
enhancing opsonization (84). Similarly, in in vitro studies, the Fc 
region of IgG-NAA has been shown to inhibit the function of B 
cells, plasma cells, dendritic cells (DC), macrophages, and neu-
trophils by binding to the inhibitory FcγRIIB receptor expressed 
by these cells. Activation of FcγRIIB by Fc region of IgG-NAA 
inhibits production of autoantibodies by B cells and plasma cells. 
Additionally IVIG ameliorates cell-mediated inflammation, e.g., 
in Kawasaki’s disease, by activating FcγRIIB and inhibiting the 
function of dendritic cells, macrophages, and neutrophils.
IgG with anti-idiotypic activity have been found in pathological 
conditions especially when there is minimal or no IgM with anti-
idiotypic activity (85) and increased levels of in vivo anti-idiotypic 
IgG has been associated with amelioration of disease activity 
mediated by pathogenic IgG autoantibodies, thus indicating that 
under pathological conditions, in  vivo IgG with anti-idiotypic 
activity is functionally active (85, 86). There are data to show 
that normal levels of IgG autoantibodies, e.g., to myeloperoxi-
dase (MPO) increase >10-fold during disease states (87) and it 
is possible that under pathological conditions when IgM-NAA 
with anti-idiotypic activity is low, there is initially a compensa-
tory increase in IgG antibodies with anti-idiotypic activity and 
the disease does not manifest clinically (85). However, with time, 
the data would also indicate that there is a decrease in the protec-
tive IgM/IgG anti-idiotypic antibodies and the disease manifests 
clinically (85). Hence, administering IVIG, which is known to 
have anti-idiotypic activity, could be beneficial in this situation 
especially if levels of both IgG and IgM-NAA are relatively low.
Pathogenic IgG Autoantibodies
Pathogenic autoantibodies that cause disease differ from IgM 
and IgG3-NAA in that they are predominantly of the IgG iso-
type, undergo somatic mutation with addition of N regions and 
these IgG autoantibodies can be either polyreactive or exhibit 
mono-reactivity. IgG autoantibodies, unlike IgM-NAA, have 
high-binding affinity (53). However, not all IgG autoantibodies 
with high-binding affinity are pathogenic in vivo and this is best 
exemplified by IgG anti-dsDNA autoantibodies (88–91). There 
are conflicting data on the B cell precursors that generate these 
pathogenic IgG autoantibodies. Data would indicate that both 
B1 and B2 cells can generate pathogenic IgG autoantibodies 
depending on the animal model used. For example, studies in 
the Fas-deficient MRL-lpr murine SLE model would indicate 
that pathogenic self-reactive IgG antibodies are generated by B2 
cells (79). However, in the NZB/W disease model of SLE and in 
a murine transgenic model of hemolytic anemia, the pathogenic 
murine IgG anti-dsDNA and anti-erythrocyte transgenic autoan-
tibodies were shown to be produced by B1 lymphocytes (21, 
92–94). Hence, removing T cells did not affect production of IgG 
anti-dsDNA or disease activity in the NZB/W model of SLE (80).
There are several mechanisms that increase pathogenic IgG 
antibody production and IgG anti-dsDNA has been most studied 
in this regard. In adolescent females with SLE and rheumatoid 
arthritis (RA) patients, there are data to show that production 
of IgG polyreactive autoantibodies results from breakdown of B 
cell tolerance mechanisms where during B cell development, B 
cells producing high-affinity IgG autoantibodies have not been 
removed or silenced either centrally in the bone-marrow or in 
the periphery before they mature into naïve immuno-competent 
lymphocytes (95, 96). Studies in healthy individuals indicate 
that 55–70% of newly generated bone-marrow B cells express 
self-reactive antibodies and most of these B cells are removed 
or silenced such that in healthy humans there remains 5–20% 
of circulating naïve B cells that continue to generate self-reactive 
IgG autoantibodies (77). However, in SLE and RA patients, owing 
to breakdown of B cell tolerance mechanisms, 25–50% of mature 
naïve B cells were found to generate self-reactive IgG autoantibod-
ies with diverse specificities (95, 96). Second, excess BAFF could 
also contribute to the breakdown of tolerance in the periphery 
as BAFF has been shown to inhibit deletion or apoptosis of self-
reactive B cells (92, 97). Elevated BAFF levels have been shown 
to be present in serum of RA and Sjogren’s syndrome (98). Third, 
there are murine studies to show that IgM-NAA-producing B1 
cells can be induced, especially with repeated immunization, 
to generate polyreactive IgG anti-self that can also react to the 
immunizing antigen. For example, B1 cells can be induced to 
generate pathogenic polyreactive IgG anti-DNA and anti-myosin 
antibodies by immunization with a hapten or an antigen derived 
from a micro-organism (99–101). Other mechanisms may, how-
ever, operate in certain other autoimmune disorders where highly 
specific IgG autoantibodies are produced, e.g., in autoimmune 
hemolytic anemia and in Factor VIII deficiency. It is possible 
that such autoimmune disorders could arise from a breakdown 
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in peripheral mechanisms such as specific deficiency of anti-
idiotypic IgM-NAA that blocks pathogenic autoantibody or 
specific deficiency of IgM-NAA that binds and masks autologous 
neo-determinants such as dsDNA.
Based on observations in the preceding paragraph, it appears 
that different mechanisms could operate in generating pathogenic 
IgG autoantibodies depending on the murine disease model. 
Additionally, the mechanisms may differ in humans even though 
the disease has similar disease manifestations. A summary of the 
existing evidence would indicate that IgG autoantibodies can be 
induced by the following mechanisms:
 (i) An excessive increase in production of pathogenic IgG 
autoantibodies relative to IgM-NAA-producing B1 cells. 
Potential mechanisms that increase self-reactive IgG anti-
bodies include lack of helper T cell apoptosis [e.g., in Fas-
deficient MRL-lpr mice (79)], excess neoantigen-driven B 
cells [e.g., in human C1q deficiency with decreased removal 
of apoptotic cells (102)], excess BAFF production [e.g., in 
patients with Sjogren’s syndrome (98)], a breakdown in B 
cell tolerance mechanisms resulting in excess naïve self-
reactive B cells [e.g., in SLE affecting young female patients 
(95)] and a deficiency in the inhibitory FcγRIIB receptor 
that normally inhibits B cells and plasma cells from produc-
ing IgG antibodies (103, 104).
 (ii) Genetic predisposition that permits some antigen-driven B1 
cell clones to acquire the ability for isotype switching and 
somatic mutation as, for example, in the NZB/W murine 
lupus model and in SPA-1 deficient mice (105, 106, 62). 
Hence, diseases induced by such defective B1 cells are ame-
liorated with administration of either polyclonal IgM or the 
specific IgM-NAA (107) or depleting B1 cells (94).
 (iii) Repeated immunization that induces isotype switching in 
B1 cells that normally generate IgM autoantibodies with 
germline genes. For example, repeated immunization with 
hapten or a streptococcal antigen can induce B1 cells to 
generate IgG antibodies of different isotypes that are poly-
reactive and bind to the immunizing antigen as well as to 
self-antigens, such as DNA or myosin (99–101).
 (iv) Excess production of a highly specific pathogenic IgG 
autoantibody by autoreactive B2 cell clones as, for example, 
in myasthenia gravis (108). Expansion of such B2 cell clones 
could have been driven by antigen, e.g., with cross-reactive 
micro-organisms in patients without thymoma (109) or be 
driven by acetylcholine receptor specific autoreactive helper 
CD4+  T cells in thymoma-associated myasthenia gravis 
where such autoreactive T cells have escaped tolerance 
mechanisms (110, 111).
 (v) Deficiency of IgM-NAA, especially IgM-NAA with anti-
idiotypic activity to a specific IgG autoantibody, thus 
incompletely neutralizing the increase in pathogenic 
IgG autoantibodies, such as antibodies to neutrophil 
cytoplasmic enzymes (myeloperoxidase, proteinase 3), 
which are commonly referred to as ANCA, dsDNA, and 
glomerular basement membrane (GBM) that are present 
in normal individuals (31, 50, 87, 112). Additionally, 
certain autoimmune disorders, such as ANCA vasculitis 
and anti-GBM nephritis, frequently occur in elderly 
patients who, with aging, can develop lower levels of 
IgM-NAA (28–32) but not IgG-NAA (33, 35, 36), which 
can increase with aging (34).
Figure 1 summarizes the role of natural and immune antibod-
ies in normal and pathological states.
Role of IgM-NAA in Protecting Against Pathogenic 
IgG Autoantibodies
SLE is the most studied autoimmune disorder where high levels 
of IgM and IgG autoantibodies, directed against nuclear antigens, 
especially dsDNA, are produced in the majority of patients. Before 
we discuss the role of IgM-NAA in protecting against pathogenic 
IgG anti-dsDNA, it would be important to indicate that a subset 
of lupus nephritis (approximately 25%) can occur in the absence 
of detectable circulating IgG anti-DNA and this is commonly 
referred to as C1q nephropathy (113, 114). The latter observations 
have led some investigators to question whether IgG anti-dsDNA 
is indeed pathogenic (115). In some patients with C1q nephropa-
thy, circulating IgG anti-dsDNA can be detected several years later 
but this subset of patients with C1q nephropathy have in general 
a better prognosis even though histologically there is similar 
glomerular immunoglobulin staining and immune deposits as 
in classical lupus nephritis (114). It is tempting to speculate that 
patients with C1q nephropathy may have high IgM-NAA and IgM 
anti-dsDNA that may be preventing detection of circulating IgG 
anti-dsDNA. A murine model with lupus nephritis but with no 
IgG anti-dsDNA in both the circulation and in kidney eluates has 
also been described (116). It is possible that in this murine model, 
the immune deposits detected in the kidney may be caused by 
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IgG complexes containing another antigen, other than dsDNA, 
and a similar mechanism could also operate in some patients with 
C1q nephropathy without circulating IgG anti-dsDNA.
However, there is evidence indicating that IgG anti-dsDNA, 
together with C1q, is an active participant in inducing or initiat-
ing glomerular damage in classical lupus nephritis with circulat-
ing IgG anti-dsDNA. First, SLE in the MRL/lpr lupus-prone mice 
is ameliorated when rendered IgG deficient by crossing these 
mice with either activation-induced deaminase (AID) or CD40L-
deficient mice (117, 118). Second, one can induce lupus nephritis 
in normal mice by either infusing purified IgG anti-dsDNA or by 
increasing in vivo IgG anti-dsDNA with use of transgenic cells or 
hybridoma cells (88–91). Importantly, not all IgG anti-dsDNA are 
pathogenic as defined by induction of lupus nephritis in vivo and 
this also may explain why certain patients with high levels of cir-
culating IgG anti-DNA are spared from lupus nephritis (88–91). 
In SLE, a potential protective mechanism involves binding of IgM 
anti-dsDNA to DNA with masking of the antigenic determinants 
that bind to IgG anti-dsDNA. Hence, lupus nephritis can occur if 
there is excess IgG anti-dsDNA or if there is a relative deficiency 
of IgM anti-dsDNA. Such a concept will explain the accelerated 
development of lupus nephritis in MRL/lpr mice lacking IgM and 
will also explain the lack of lupus nephritis in patients having 
high IgG anti-dsDNA and high IgM anti-dsDNA or IgM-NAA 
(119, 120). This latter possibility may also explain why FcγRIIB-
deficient Balb/c mice are more resistant to developing lupus 
nephritis when compared to FcγRIIB-deficient C57BL/6 mice 
(121). In both mice, there is excess IgG anti-dsDNA production 
due to lack of the inhibitory FcγRIIB receptor but Balb/c mice 
have significantly higher levels of plasma IgM when compared to 
C57BL/6 mice (122–124).
Several observations would suggest a role of IgM-NAA in 
protecting normal individuals and patients with autoimmune 
disorders from such self-reactive IgG antibodies. The protec-
tive role of IgM-NAA is best exemplified in murine models of 
SLE, where enhancing IgM anti-dsDNA levels or infusing IgM 
anti-dsDNA, ameliorates disease activity (107, 125, 126). Well 
studied mechanisms by which IgM-NAA can induce protection 
and prevent inflammation include (i) removing neo-antigens by 
binding of IgM-NAA to oxidized neo-determinants and removal 
of IgM/C1q bound antigens by phagocytosis, e.g., IgM anti-PC 
(127), (ii) inhibition of the pathogenic IgG autoantibody induced 
inflammatory response by IgM-NAA, e.g., IgM-ALA (128), (iii) 
neutralization of pathogenic IgG autoantibodies by IgM-NAA 
having anti-idiotypic activity (129), (iv) preventing binding of IgG 
to antigenic determinants by competitive inhibition even though 
these IgM-NAA have lower binding affinity (129), (v) inhibiting 
complement activity by binding of IgM to complement compo-
nents (17), and (vi) inhibiting generation of IgG autoantibodies 
possibly by binding of IgM-NAA to endogenous autoantigens/
neo-antigens or to the B cell FcμR (64, 65, 119, 130–132).
The above mechanisms may explain why mice without 
secretory IgM have increased IgG autoantibodies, including 
anti-dsDNA, with aging (119, 120). This would also explain 
why B1-deficient SJL mice are more susceptible to induction of 
experimental autoimmune thyroiditis or allergic encephalitis 
cells (133). Conversely, such a concept would also explain why 
disease activity in SLE patients is less severe with high levels of 
IgM anti-dsDNA and other IgM-NAA (125, 134, 135). The above 
mechanisms may also explain why several autoimmune disorders 
are helped by either increasing production of in vivo IgM-NAA 
(126) or administering either pooled polyclonal IgM or a specific 
IgM-NAA (110, 129, 136). The latter is best exemplified by IgM 
anti-dsDNA where infusion of a specific IgM-NAA ameliorated 
SLE-induced nephritis in NZB mice (107).
Presence of pathogenic IgG autoantibodies leads to a compen-
satory increase in IgM–NAA, such as IgM anti-PC, IgM-ALA, and 
IgM/IgG anti-idiotypic antibodies, to counter these pathogenic 
IgG antibodies as well as inflammation initiated by the excess 
IgG self-reactive antibody. It is also possible, that over time, the 
production of IgM and IgG anti-idiotypic antibodies may not be 
able to keep up with the relatively high production of pathogenic 
IgG autoantibody and the disease becomes symptomatic. Hence, 
the initial increase in IgM-NAA and IgG anti-idiotypic antibody 
levels could explain the asymptomatic nature of the disease 
despite increased levels of IgG anti-dsDNA and other anti-nuclear 
antibodies several years before clinical onset of disease (85, 137). 
Additionally, there could be a heightened compensatory response 
of other immuno-regulatory mechanisms, e.g., increase in T-regs 
or IL-10 in B1 cells, which could inhibit the clinical onset of 
disease or ameliorate disease activity in these patients and other 
animal models. The latter is best exemplified in mice with secre-
tory IgM deficiency, where despite total lack of circulating IgM 
and increased IgG3 anti-dsDNA (120), these cellular compensa-
tory mechanisms inhibit development of autoimmune disease 
including lupus nephritis (63, 119). It is also possible that IgG3 
anti-DNA is not pathogenic and their increased production by 
B1 cells, in secretory IgM deficiency (120), may be protective. 
However, in situations where inflammation has been experimen-
tally induced or there is an excessive increase in production of 
pathogenic IgG autoantibodies or increased apoptosis, then these 
cellular regulatory mechanisms cannot effectively compensate for 
lack of IgM and this leads to a more severe and rapid worsening 
in disease activity. For example, SLE disease is more severe in the 
MRL-lpr mice when these mice are crossed with secretory IgM 
deficient mice (120). Similarly, secretory IgM-deficient mice are 
prone to develop a more rapid and severe inflammatory response 
after renal ischemia or allogeneic cardiac transplantation (138).
Physiological Role of igM-NAA
IgM–NAA, which are spontaneously secreted by B1 and MZB 
cells, are polyclonal and exhibit a diverse repertoire of antigen 
specificities, many of which are polyreactive and, hence, cross-
react with foreign antigens or pathogens. Additionally, B1 and 
MZB cell clones can be activated either by their TLR or BCR by 
both endogenous and foreign antigens. These special characteris-
tics of IgM-NAA, together with the low-binding affinity (but with 
high-binding avidity owing to its pentameric structure), have 
allowed these antibodies to acquire functions that are not char-
acteristic of the highly specific immune IgM and IgG antibodies. 
Physiological functions that have been attributed to IgM-NAA 
have included the following:
FiGURe 2 | evaluating the inhibitory effect of human monoclonal igM 
and polyclonal igM on R5-8658 and X4-iiiB Hiv viruses. (A) Specificity 
of umbilical cord B cell clone IgM was characterized by binding of IgM, to 
recombinant CD4 and to leukocytes, which is depicted below each clone. 
IgM from B cell clones was used at concentration of 3 μg/ml, while purified 
IgM from normal serum (positive control) was used at 10 μg/ml. B cell clone 
2E11-H4 with no IgM-ALA and no anti-CD4 activity was used as a negative 
control. Without IgM, p-24 levels for R5-8658 and X4-IIIB were 87,500 and 
126,000 pg/ml, respectively. These data are representative of three different 
experiments. (B) The inhibitory effect of normal polyclonal IgM (5 μg/ml) on 
HIV-1 infection (single cycle replication) of GHOST cells that express GFP 
upon integration on viral HIV-1 DNA. IgM was present throughout the culture 
period and added to cells 15 min before adding virus. These are 
representative examples of five separate experiments. Figure and legend 
reproduced with permission from Ref. (144). Copyright 2008. The American 
Association of Immunologists, Inc.
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 (i) Countering the pathogenic effects of the normally present 
IgG autoantibodies that escape B cell tolerance mechanisms. 
Potential strategies employed by IgM-NAA for this purpose 
include (a) neutralization of these IgG autoantibodies by 
anti-idiotypic mechanisms (129), (b) masking endogenous 
antigens (129), and (c) inhibiting the expansion of B2 cell 
clones that produce these IgG autoantibodies (79, 126). We 
have discussed these mechanisms in an earlier section of this 
review. However, the most compelling data demonstrating 
that IgM-NAA can counter pathogenic IgG autoantibodies 
are studies in murine models of SLE where administration 
of IgM anti-DNA or increasing expression of IgM anti-DNA 
in MRL-lpr mice (by crossing MRL-lpr mice with transgenic 
mice expressing IgM anti-DNA) ameliorated disease activity 
(107, 126).
 (ii) Providing the first line of defense against pathogens while 
the adaptive immune system, i.e., B2 and T cells, are being 
deployed to mediate a more specific and effective immune 
response that is long lasting and has memory. The role of NAA 
in mediating protection against pathogens was first brought 
to light by the observation that NAA recognize bacterial 
toxins and several viral antigens (139, 140). Second, the 
creation of mice deficient in secretory IgM clearly aided in 
analyzing the protective role of both natural and immune 
IgM (63, 141). This topic will be briefly discussed as there 
are several excellent and detailed reviews on this subject (55, 
141). Briefly, IgM-NAA mediates this protection through 
several mechanisms. First, each natural IgM clone, by hav-
ing a pentavalent structure and by being polyreactive, can 
simultaneously bind to different conserved structures, such 
as nucleic acids, phospholipids, and carbohydrates, on the 
same pathogen and inhibit the pathogen from invading cells 
and disseminating into different organs. Second, the early 
components of complement, such as C1q, bind to the IgM 
complexed to the invading organism. Complement binding 
to IgM not only enhances neutralization of pathogens, e.g., 
certain viruses and bacteria, but also enhances phagocytosis 
of pathogens by macrophages and dendritic cells. The 
importance of either natural or immune IgM in limiting 
infection varies with different pathogens and this subject 
has been well reviewed (55, 141). Third, normally present 
IgM-NAA has significant levels of IgM anti–PC, which can 
readily bind to PC that is attached to sugar residues on the 
cell membranes and cell walls of many invading organisms 
(142). PC was first detected in 1967 on S. pneumoniae (143) 
and subsequently found to be present on many bacteria, 
protozoa, fungi, and nematodes (142). Infection with many 
of these organisms increases levels of IgM anti-PC, which 
in the presence of C1q enhances phagocytosis of these 
organisms and inhibits an excess inflammatory response 
by mechanisms discussed below. Finally, we have shown 
that IgM-NAA can limit HIV infection, both in vitro and in 
humanized SCID mice through another mechanism, that is 
by inhibiting T cell activation (39) as well as by binding of 
natural IgM to CD4 and chemokine receptors and inhibiting 
HIV entry into cells (Figure 2) (39, 144).
 (iii) Inhibiting IgG autoantibody production and inflammatory 
responses by clearing apoptotic cells and binding to oxidized 
neo-determinants. Apoptotic cells that are normally pro-
duced in large numbers, express oxidized neo-determinants. 
Several homeostatic mechanisms, including binding of C1q 
and mannose binding lectin (MBL) to apoptotic cells, are 
involved in inducing macrophages and DC to phagocytose 
apoptotic cells and nuclear antigens [reviewed in Ref. (145)]. 
IgM-NAA are also involved in enhancing this phagocytic 
process, especially after tissue injury of nerves (69), and in 
inducing an anti-inflammatory effect (56). Several IgM-NAA 
antibodies have been identified, each with binding specific-
ity to certain oxidized neo-determinants, including PC, 
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malondialdehyde (MDA), cardiolipin, phosphatidylserine, 
and Annexin IV present on apoptotic cells and not live cells 
(146). The best-studied IgM-NAA reactive to apoptotic cells 
is the IgM anti-PC antibody (also referred to as T-15), which 
binds to a dominant oxidized neo-determinant on apoptotic 
cells. Both in  vitro and in  vivo studies, using monoclonal 
IgM anti-PC, have clearly shown that phagocytosis by DC 
and macrophage is enhanced when C1q or MBL binds to the 
IgM/apoptotic cell complex. In these in vivo studies, either 
endogenous production of IgM anti-PC was increased by 
administering large numbers of apoptotic thymocytes 
(2.5 × 107) or mice were given 1.5–2 mg of a monoclonal 
IgM anti-PC preparation that bound to endogenous apop-
totic cells. Hence, natural IgM anti-PC inhibits production 
of pathogenic IgG autoantibodies by masking oxidized 
neo-determinants and enhancing removal of apoptotic 
cells. However, enhancing apoptotic cell phagocytosis by 
DC also inhibits DC maturation/activation and induces 
an anti-inflammatory effect with decreased production of 
pro-inflammatory cytokines and an increase in levels of 
splenic regulatory B cells (127, 147). Additionally, repeated 
weekly infusions of monoclonal IgM anti-PC or apoptotic 
thymocytes inhibited development of arthritis and induced 
regulatory B cells in mice (127, 147).
Natural IgM autoantibodies has also been shown to bind 
to various oxidation-specific neo-determinants, specifically 
PC and MDA present on oxidized LDL lipids, but not native 
LDL (146, 148, 149). High levels of IgM anti-PC and IgM 
anti-MDA were also found in ApoE-deficient mice that 
have high circulating cholesterol and severe atherosclerosis. 
It has been suggested that oxidized lipids, in this murine 
model, induces these high IgM anti-PC/MDA antibodies 
as a protective mechanism. Supporting such a concept are 
other observations showing an association of high in vivo 
levels of IgM anti-PC and reduced atherosclerotic plaques in 
both patients and different animal models [reviewed in Ref. 
(56)]. Similarly, there are studies showing that immuniza-
tion of LDL receptor knockout mice with the S. pneumoniae 
vaccine induces IgM anti-PC and this is associated with 
less atherosclerotic lesions (150). Several mechanisms have 
been postulated to explain the amelioration of atheroscle-
rotic lesions by IgM anti-PC in these murine models of 
atherosclerosis. First, IgM anti-PC masks the PC containing 
neo-determinants on oxidized lipids, thus inhibiting uptake 
of these lipids by macrophages and this leads to a decrease 
in foamy macrophages that are part of the atherosclerotic 
plaque (151). Second, IgM anti-PC, together with C1q, 
enhances phagocytosis of apoptotic foamy macrophages 
containing high levels of lipids. Enhanced phagocytosis of 
apoptotic macrophages, especially by DC, inhibits DC matu-
ration/activation and induces an anti-inflammatory milieu 
(127, 147). Data demonstrating increased atherosclerosis in 
secretory IgM-deficient mice or in C1q ko mice would lend 
support to the role of IgM anti-PC and C1q in inhibiting 
atherosclerosis (102, 141, 152–154).
The finding that both IgM-deficient mice and C1q 
knockout mice have increased apoptotic cells as well as 
develop SLE would indicate that both IgM anti-PC and 
C1q are required to effectively remove or clear apoptotic 
cells (155, 156). The latter studies would also indicate that 
inefficient clearance of apoptotic cells, including nuclear 
antigens, induces development of pathogenic IgG autoanti-
bodies and SLE. However, ineffectual clearance of apoptotic 
cells cannot entirely explain the increased propensity of 
IgM-deficient mice to develop autoimmunity and more 
severe atherosclerosis when compared to C1q ko mice as 
both mice have similar number of apoptotic cells in the 
atherosclerotic plaques and the C1q ko mice has in addi-
tion, circulating apoptotic cells that should have worsened 
atherosclerosis (102, 141, 155). Such observations would 
indicate that IgM-NAA regulates inflammation by other 
additional mechanisms (to be presented below) besides 
enhancing phagocytosis of apoptotic cells.
 (iv) Inhibiting inflammation by binding of IgM-NAA to receptors 
on live leukocytes, i.e., via IgM-ALA. The existence of this 
IgM-NAA subset was known since 1970 (157). Their role 
in inflammation was recognized when several investigators 
showed that the level of these antibodies, like IgM anti-PC, 
increased with diverse infections and inflammatory states 
[reviewed in Ref. (39)]. However, it was unclear whether 
IgM-ALA were pathogenic or not. The idea that IgM-ALA 
may have anti-inflammatory function and may be protective 
came from observations in allograft recipients where patients 
with high levels of IgM-ALA were found to have significantly 
less rejections and developed less alloantibodies after allo-
immunization (Figure 3) (39, 131). We hypothesized that 
these natural IgM-ALA increase during inflammatory states 
to regulate leukocyte function and prevent excess inflamma-
tion that may be detrimental to the host. Two characteristics 
inherent in IgM-ALA allowed us to make this hypothesis. 
First, we showed that these antibodies bind with low affinity 
to different leukocyte receptors, including co-stimulatory 
molecules and chemokine receptors (4, 39). Second, we and 
other investigators observed that these complement fixing 
antibodies did not lyse leukocytes at body temperature but 
readily lysed cells at room temperature or colder tempera-
tures in the presence of complement (131, 157, 159). This 
non-lytic nature of these antibodies at body temperature led 
us to hypothesize that IgM-ALA, by binding to receptors on 
live leukocytes at body temperature, could alter or regulate 
their function. Initially, with in vitro studies using human 
IgM, we showed that the repertoire of IgM-ALA varies 
among individuals during health and in disease and, second, 
that IgM-ALA regulates the function of both human and 
murine T cells and dendritic cells (4, 39, 138). Additionally, 
in murine models, we showed that increasing in vivo levels 
of IgM-ALA with physiological doses of purified polyclonal 
IgM, i.e., 150 μg/mouse, every 3 days, protected mice from 
(a) renal ischemia reperfusion injury (IRI), (b) ameliorated 
rejection in a fully mis-matched cardiac allograft model, 
and (c) protected NOD mice from developing autoimmune 
insulitis and diabetes. In further experiments, we show that 
the protective effect in the model of innate inflammation 
(i.e., renal IRI) is mediated in part by IgM-ALA binding 
TABLe 1 | Physiologic function of non-pathogenic autoantibodies.




Binds to bacteria and enhances 
phagocytosis (req. C1q, Fcα/μR)
Binds to bacteria and 
enhances phagocytosis 




Blocks anti-self IgG Ab 
(anti-idiotypic)
Blocks anti-self IgG Ab 
(anti-idiotypic)
IgM masks neo-antigen Binds to nuclear and 
cytoplasmic debris and 
enhances phagocytosis 
(req. C1q, MBP)
Binds to apoptotic cells (PC), 
nuclear and cytoplasmic debris and 




Anti-complement Regulates B cells, 




IgM-ALA regulates DC and T cells, 
and enhances Tregs by binding to 
CD40, CD86, CD4, CD3, and TcR




IgM regulates B1 cell expansions 
via FcμR
IgG regulates B1 and 
B2 cell expansion via 
FcγRIIB
FiGURe 3 | High levels of serum igM-ALA in transplant recipients are associated with better kidney allograft survival and decreased alloantibody 
levels. (A) Dot plots labeled “baseline” depict IgM staining on B lymphocytes, but not on T cells, in the absence of sera. The lower panels (after adding sera) depict 
differences in the level of IgM bound to donor T lymphocytes (IgM-ALA) after addition of pre-transplant serum from different ESRD patients. (B) Alloantibody titer in 
sera measured by cytotoxicity is correlated to presence of IgM autoantibody to leukocytes. (C) The difference in percentage of acute rejections and graft loss 
comparing high IgM-ALA vs. the no and low IgM-ALA groups. MCF indicates increase in mean channel fluorescence of anti-IgM staining after addition of serum. 
Figure and legend reproduced with permission from Ref. (131) copyright 1981 Wolters Kluwer Health Inc. (B) Figure and legend reproduced with permission from 
Ref. (158). Copyright 2010 Springer Science + Business Media LLC (A,C).
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to activated/mature DC and regulating their function (4). 
In a later section, we will review in more detail the above 
data on IgM-ALA. We plan to show that the observed anti-
inflammatory effects of polyclonal IgM was predominantly 
from IgM-ALA and not from IgM anti-PC that bound to 
apoptotic cells.
 (v) Inhibiting expansion of B1 cells and enhancing antigen 
presentation to B2 and helper T cells in splenic lymphoid 
follicles. This physiological function of IgM became obvious 
in mice with secretory IgM deficiency as well as in mice 
with FcμR deficiency. B1 cells in the splenic marginal zone 
increased several fold in mice deficient in IgM while levels 
of IgM increased in FcμR-deficient mice indicating that IgM 
maintains B1 cell homeostasis and levels of natural IgM by 
binding to FcμR (63, 64, 66, 160). Second, both these mice 
have impaired immune IgG response to protein antigens, 
especially with low dose antigen, indicating that IgM facili-
tates antigen trafficking from the splenic marginal zone to 
the B2 cell rich lymphoid follicles via FcμR bound IgM/
antigen complexes (63, 160).
The above observations indicate that IgM-NAA protect the 
host from invading organisms and more importantly maintain 
several homeostatic mechanisms primarily aimed at preventing 
autoimmunity and over exuberant inflammation, which can have 
detrimental effects on the host. Table 1 summarizes some of the 
physiological and pathological concepts outlined above. Several 
observations indicate that infective and other inflammatory states 
increase all IgM-NAA subsets, especially IgM anti-PC to clear 
the increased production of apoptotic cells that could trigger 
autoimmunity and, second, increase IgM-ALA to subdue excess 
inflammation that can be detrimental to the host [reviewed in 
Ref. (56) and next section]. Based on the preceding observations, 
one could predict that a decrease in IgM-NAA, as can occur in 
aging (28–30), could predispose to increased autoimmunity and 
increased morbidity and mortality from an excess inflammatory 
response, for example with infections.
Pathogenic effects of igM-NAA Under 
Non-Physiological Conditions
Certain IgM-NAA which under physiological conditions are 
protective and anti-inflammatory can under non-physiological 
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conditions become pathogenic and induce inflammation. In this 
section, we will present some of the conditions that can induce 
certain protective IgM-NAA to become pathogenic.
 (i) Induction of pathogenesis by binding of IgM-NAA at cold 
temperatures: This is best exemplified in human renal 
allograft transplant recipients having high IgM-ALA and 
IgM-anti endothelial cell antibody (IgM-AEA) levels at the 
time of the kidney transplant. These recipients have a high 
incidence of delayed kidney graft function (DGF) (161, 
162) resulting from high levels of IgM-AEA which cause 
glomerular endothelial cell injury when, after successful 
vascular anastomosis, warm blood is allowed to flow into 
a cold kidney. Fortunately, this self-limiting injury is pre-
vented by warming the kidney prior to re-instituting blood 
flow. Such observations highlight the nature of IgM-NAA, 
i.e., their potential for complement mediated cytotoxicity 
under non-physiological cold conditions (157, 159).
 (ii) Induction of pathogenesis by binding of natural IgM to 
unmasked neo-antigens. This is best exemplified by the 
ubiquitous neo-antigen “non-muscle myosin heavy chain 
type IIA and C (NMM)” which is unmasked in murine 
models of acute ischemia to the small bowel, skeletal mus-
cle (hind limb) and heart. About 1–2% of IgM-NAA B1 cell 
clones in mice secrete IgM anti-NMM probably to protect 
against NMM derived from infectious organisms (163, 
164). In murine models of acute ischemia to the bowel or 
hind limb, injury is predominantly mediated during reper-
fusion by innate inflammation triggered by IgM binding to 
the unmasked NMM and activation of complement (6, 163, 
165, 166). RAG-1 ko mice are normally protected from this 
ischemic injury to the small bowel or hind limb (163, 166). 
However, RAG-1 ko mice succumb to this ischemic injury 
after infusion of polyclonal IgM or monoclonal IgM anti-
NMM. Additionally, one can clearly demonstrate binding 
of IgM and complement to NMM in bowel epithelial cells 
or to hind limb striated muscle cells (163, 165).
Interestingly, one does not observe innate inflammation 
mediated by IgM anti-NMM after murine renal ischemia 
even though endothelial cells in glomeruli and peri-tubular 
capillaries express NMM (167, 168). One possibility is that 
NMM in the peri-tubular capillaries or in the tubules is 
not unmasked after ischemia. After renal IRI, most of the 
ischemia induced kidney injury occurs in the outer medul-
lary renal tubules. However, after renal IRI, one can detect 
increased IgM binding to glomeruli but not to the extensive 
network of NMM containing capillaries that surround the 
tubules or the renal tubules (168). Additionally, depleting B1 
cells, decreased binding of IgM to glomeruli, and decreased 
glomerular injury, but did not protect tubules from 
inflammation-mediated renal injury, thus indicating that 
the innate inflammation seen after renal IRI is not mediated 
by natural IgM and complement (168). Other studies would 
indicate that the inflammatory response after renal IRI is 
mediated by ischemia-induced renal tubular injury that 
activates innate immune cellular mechanisms involving NK 
and NKT cells (169). This latter study would also explain 
why Rag-1 ko mice and IgM ko mice without secretory IgM 
are not protected from renal IRI (4, 138, 170–172).
 (iii)  Induction of pathogenesis by non-physiologic expansion of 
specific IgM-NAA clones. This is best exemplified by expan-
sion of certain B1 cell clones that specifically secrete rheu-
matoid factor (RhF), an IgM-NAA that binds to self IgG. 
Excess production of RhF predisposes to generation of large 
circulating IgM/IgG complexes (referred to as cryoglobulins 
as these complexes precipitate ex vivo in the cold) that cause 
thrombosis of small blood vessels especially in the kidney 
glomeruli and skin (173, 174). This serious clinical problem 
is treated by plasmapheresis (to remove cryoglobulins) and 
agents to deplete B cells. The most common etiology for 
monoclonal or polyclonal expansion of RhF secreting B1 
cell clones is chronic hepatitis C infection. Currently, it is 
unclear why this viral infection is associated with clonal 
expansion of RhF secreting B1 clones. More importantly, 
even though RhF was the first IgM-NAA to be discovered, 
we do not understand their normal physiological role.
Nature of igM-ALA and Understanding 
Their Anti-inflammatory Function
In this section, we review some of our pertinent observations 
on IgM-ALA that initially were discovered because of their 
lymphocytotoxic activity at room temperature in the presence 
of complement [reviewed in Ref. (39)]. Here, we show (a) that a 
substantial subset (8–10%) of IgM secreting human B cell clones, 
obtained from the umbilical cord, has IgM-ALA activity, (b) that 
polyclonal IgM-ALA clones have binding specificity to certain 
leukocyte subsets and that polyclonal IgM-ALA will bind to only 
some leukocyte receptors and not others. More importantly, 
we show that the repertoires of IgM-ALA vary in disease states 
among different individuals, and (c) that IgM-ALA exhibits 
anti-inflammatory effects, both in vitro and in vivo. We show that 
the anti-inflammatory effects are in part explained by IgM-ALA 
binding to co-stimulatory receptors and regulating the function 
of T effector cells and DC without decreasing Tregs. These in vitro 
studies involve human and murine cells, while in  vivo studies 
were performed in mice.
Human Umbilical Cord B Cell Clones Produce 
IgM-ALA that Exhibit Leukocyte Receptor 
Specificity – Binding of IgM to Leukocytes was Not 
Mediated by FcμR
We initially wanted to determine if IgM-ALA exhibited leuko-
cyte receptor specificity as natural antibodies are polyreactive 
and, hence, each monoclonal IgM could non-specifically bind to 
carbohydrate or other moieties on several leukocyte receptors. 
We isolated B cell clones from human umbilical cord blood and 
observed that >90% of B cells were IgM secreting with about 
10% of the IgM clones having IgM-ALA binding activity when 
examined by flowcytometry on a cell mixture comprising of B 
(Daudi), T (Jurkat, Sup T1), and macrophage (U937) human 
cell lines. The lack of demonstrable leukocyte reactivity by the 
majority of IgM clones would indicate that IgM did not bind 
to FcμR on human B cells and macrophages (175). Second, we 
FiGURe 5 | immunoprecipitation experiments to show binding of 
human polyclonal igM to CD3, CD4, CCR5, and CXCR4. (A,B) 
Identical quantities of individual (labeled no. 1, 2, etc.) or pooled 
(labeled P) IgM from normal (labeled N), HIV (labeled H), ESRD (labeled E), 
or Waldenstrom (labeled W) were used to immunoprecipitate leukocyte 
receptors from equal amounts of whole cell lysates or recombinant soluble 
CD4. As controls, Western blots were performed with cell lysates in the 
absence of agarose beads [to control for binding of primary Ab to  
leukocyte receptor and to determine receptor size (labeled Ly)]. In another 
control, agarose beads without IgM were added to lysate to determine 
whether the leukocyte receptor non-specifically bound to the bead  
(B plus Ly). Note that several fold more receptors were immunoprecipitated 
by ESRD and HIV IgM when compared with normal IgM. (C) Significantly 
increased binding of IgM from B cell clone 4G4 to CD4+ T cells when 
compared with CD4− T cells (MCF 71.6 vs. 16.6). Clone 4G4 secreted IgM 
with anti-CD4 reactivity. Note that no increased binding was observed on 
CD4+ T cells using a B cell clone (IE12) secreting IgM without anti-CD4 
reactivity (MCF 22.5 vs. 22.3). Figure and legend reproduced with  
permission from Ref. (39). Copyright 2008. The American Association of 
Immunologists, Inc.
FiGURe 4 | Presence of igM-ALA in supernatants from umbilical cord 
B cells. (A,B) IgM-ALA reactivity in IgM containing supernatants from B cell 
clones activated with the EBV virus. IgM-ALA reactivity was detectable in 8 of 
79 supernatants. (A) Supernatants were interacted with cells containing a 
mixture of cell lines, i.e., Jurkat, SupT-1, Daudi, and U937. Note that the 
supernatants have IgM-ALA that is specific for either T or non-T cells or all 
four cell lines. Subsequent studies revealed that IgM anti-non-T cell had 
binding reactivity to only U937 cells and not to Daudi cells. (B) Data on IgM 
anti-CD4 reactivity using an ELISA technique. Note that only 2 of 79 
IgM-containing supernatants had IgM anti-CD4 reactivity and both these 
supernatants also had IgM with binding to leukocytes. Figure and legend 
reproduced with permission from Ref. (39). Copyright 2008. The American 
Association of Immunologists, Inc.
11
Lobo Natural Autoantibodies and IgM Anti-Leucocyte Autoantibodies
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 198
observed that these IgM-ALA clones exhibited leukocyte subset 
specificity in that some of the IgM-ALA monoclonal antibodies 
only bound to receptors expressed by all leukocytes or either T 
cells (SupT-1, Jurkat) or macrophages (U937) or B cells (Daudi) 
(Figure  4) (39). Further studies revealed that only human 
monoclonal IgM, having T cell reactivity, immunoprecipitated 
CD4 from cell lysates and bound to recombinant soluble CD4, 
thus indicating that IgM-ALA can exhibit both receptor and cell 
specificity.
Polyclonal IgM from Different Human Sera Differ in 
Their Repertoire for Receptor Binding. IgM, in 
Addition, Regulates Human T Effector Cells and DC 
Without Affecting Tregs or Chemokine Production
We used polyclonal IgM, purified by size exclusion chromatogra-
phy, from sera of normals, HIV patients and renal dialysis (ESRD) 
patients (39). Ammonium chloride precipitation was not used as 
this method affected IgM-ALA binding [see method details in 
Ref. (39)]. We showed that IgM could immunoprecipitate CD3, 
CD4, CCR5, and CXCR4 from lysates of cell lines (Figure  5). 
However, the repertoire of IgM-ALA was found to be different 
among individuals, especially patients as exemplified with HIV 
patients (see Figure 5). Such differences in the repertoires of IgM-
ALA may explain why clinical manifestations of inflammation 
are different among different individuals. It is also possible that 
prior exposure to different infective agents or foreign antigens 
may explain the observed differences in the repertoire of IgM-
ALA among different individuals (31).
In in vitro studies with human peripheral blood mononu-
clear cells (PBMC), addition of polyclonal human IgM, but not 
human IgG or Waldenstrom’s IgM lacking IgM-ALA, differen-
tially inhibited co-stimulatory receptor upregulation, cytokine 
production, and proliferation of T cells (39). Both normal 
and patient IgM downregulated expression of CD4, CD2, and 
CD86 but not CD8 and CD28 on blood PBMC activated with 
FiGURe 6 | Polyclonal igM inhibits iFN-γ production and T cell proliferation and differentiation into TH-1 and TH-17 cells of murine splenic cells and 
specific pro-inflammatory cytokines from human leukocytes activated with alloantigens. (A) Supernatant IFN-γ in 48 h culture media of splenic cells 
activated with a-gal-ceramide that specifically activates NKT-1 cells. IgM was added either 0.5 h before activation (IgM pre) or 1 h post activation. (B–D) CFSE 
labeled WT-B6 splenocytes (2.5 × 105 in 0.5 ml media) were activated either in a one-way MLR (using 7.5 × 05 BALB/c irradiated splenocytes) or LPS (350 ng) and 
soluble anti-CD3. Cells were cultured for 4 to 5 days. IgM (10–15 μg) was added at the initiation of culture unless otherwise indicated. In (D), the effect of Tregs was 
evaluated by co-culturing 2.5 × 105 CD45.1 WT-B6 splenic leukocytes, containing 1.8% CD4+ Foxp3+ cells, with 0.5 × 105 CD45.2 WT-B6 Tregs (76% Foxp3+) 
under cytokine conditions favoring TH-17 differentiation. (e) Pooled human normal, ESRD, and HIV IgM but not Waldenstrom IgM significantly inhibit the increase in 
TNF-α and IL-13 but not that of IL-6, IL-8, MIG, and MCP-1 produced in response to alloantigen activation of T cells. Supernatants were obtained from day 5 MLR 
cultures stimulated in the presence or absence of pooled IgM (15 μg/ml), added on day 0. (F) Pooled human IgM inhibits anti-CD3-mediated Zap-70 
phosphorylation of human T cells. IgM was added 30 min before anti-CD3/28 and cells were cultured overnight before quantitation with flowcytometry. Figures and 
legend reproduced with permission from Ref. (138) (A–D) and (39) (e,F). Copyright 2008 and 2012. The American Association of Immunologists, Inc.
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alloantigens (MLR) (39). Additionally, both normal and patient 
IgM inhibited production of the same set of cytokines, i.e., TNF-
α, IL-13, and IL-2 but not IL-6 and chemokines when human 
PBMC were activated by alloantigens [Figure  6E; Ref. (39)]. 
Other investigators working with a monoclonal IgM-ALA with 
reactivity to TcR have shown that IgM-ALA can inhibit IL-2 
production and T cell proliferation by binding to the TcR (5, 
176). Similarly, we showed that IgM inhibited T cell prolifera-
tion induced by alloantigens or CD3 ligation and also inhibited 
Zap-70 phosphorylation induced by anti-CD3 [Figure 6F; Ref. 
(39)]. However, IgM did not alter chemokine production by 
activated PBMC but inhibited chemokine-induced chemotaxis 
by binding to the receptor and blocking chemokine binding 
(39). Importantly, IgM did not alter Treg levels in an MLR, 
despite inhibiting T cell proliferation. In general, identical 
quantities of patient IgM had a more inhibitory effect in the 
above studies when compared to normal IgM (39). These 
functional differences between normal and patient IgM may 
be explained by differences in their quantity and IgM-NAA 
repertoire (Figure 5). Other investigators have also shown that 
polyclonal human IgM can inhibit proliferation of human T 
cells (5, 177).
In summary, the data indicate that polyclonal IgM, in 
physiological doses, inhibit human T effector cell activation 
and proliferation as well as regulates production of certain 
cytokines by binding to certain co-stimulatory molecules 
(CD4, CD3, TcR). IgM does not inhibit T regs. We also show 
that the quantity and repertoire of IgM-ALA varies in different 
individuals especially in disease. Interestingly, IgM-ALA does 
not appear to affect the production of chemokines by leuko-
cytes, but interferes with their action by binding to chemokine 
receptors.
FiGURe 7 | Polyclonal murine wT igM bind to membrane receptors on 
leukocytes. (A) Polyclonal IgM has several fold increased binding to 
activated murine splenic B cells and dendritic cells (DC). Splenic leukocytes, 
activated for 48 h were interacted with purified mouse IgM at 4°C and 
evaluated for IgM binding using IgG anti-IgM (clone 11/41). Isotype 
monoclonal IgM with reactivity to KLH did not bind to activated leukocytes 
(data not shown). IgM binding to B cells was evaluated by blocking 
intrinsically expressed IgM with unlabeled IgG anti-IgM (clone 11/41). (B) It 
depicts immunofluorescence microscopy images of IgM binding to cell 
membranes of splenic T lymphocytes. (C) It compares binding of IgM and 
isotype IgM on CD3+WT-B6 pronase pretreated splenic leukocytes. Spleen 
cells were pronase digested to remove FcμR and to show that IgM-ALA can 
bind to other receptors on cell membranes. (D) It depicts a representative 
example of a Western blot from two separate experiments demonstrating 
immunoprecipitation by WT-polyclonal IgM of biotinylated membrane proteins 
from the murine macrophage cell line J77. In this experiment, WT-polyclonal 
IgM is compared with an equal amount of isotype IgM that has no binding 
activity to leukocytes using flow cytometry. Figure and legend reproduced 
with permission from Ref. (4) (A) and Ref. (138) (B–D). Copyright 2012 and 
2015. The American Association of Immunologists, Inc.
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Polyclonal Murine IgM Binds to Specific  
Co-Stimulatory Receptors and Regulates the 
Function of Murine T Effector Cells, DC, and NKT 
Cells but Not Tregs
In murine studies, we initially observed that IgM-ALA bound to 
pronased splenic leukocytes (Figures 7B,C)  and that IgM-ALA 
had several fold increased binding to live splenic granulocytes, 
DC, and B cells when compared to T cells and IgM binding to 
all leukocytes was enhanced when cells were activated (see 
Figure  7A). Furthermore, we showed that IgM-ALA bound to 
splenic leukocytes independently of FcμR and, second, showed 
that IgM, after binding to leukocytes, could immunoprecipitate 
several different leukocyte receptors (Figure  7D) (138). These 
observations, together with the above findings with human leu-
kocytes, led us to investigate if IgM had an inhibitory effect on the 
function of T cells, DC, and NKT cells by binding to receptors, 
e.g., antigen-presenting receptors and co-stimulatory receptors, 
that get upregulated during activation. Both T cells and DC have 
an important role in adaptive immunity, e.g., in transplantation 
and NKT cells, together with DC, have an important role in innate 
immunity.
With murine leukocytes, we showed in in vitro studies, that 
physiological doses of murine polyclonal IgM inhibited naïve 
T cells from differentiating into TH-1 and Th-17 cells even when 
IgM was added 48 h after activation (Figures 6B–D) (138). This 
inhibitory effect of IgM-ALA on T cells did not depend on pres-
ence of DC as the same inhibitory effect was noted when T cells 
were activated with insoluble anti-CD3/28. IgM inhibition of 
anti-CD3-mediated Zap-70 phosphorylation would indicate that 
the inhibitory effect of IgM on T cell function is mediated by IgM 
binding to CD3 [Figure  6F; Ref. (39)]. IgM did not, however, 
inhibit differentiation of murine T cells into Foxp3+ cells and, 
furthermore, under Th-17 differentiating cytokine conditions, 
IgM inhibited sorted Foxp3+ cells from differentiating into 
TH-17 cells (Figure 6D) (138).
Since there are <1.5% of DC in murine splenic leukocytes, 
we used 7–8 day cultured murine bone-marrow DC (BMDC) to 
investigate the functional effects of IgM on DC (4). We showed 
that polyclonal murine IgM, but not IgM pre-adsorbed with 
activated splenic leukocytes, bound to recombinant soluble CD40 
and PD1 but not PDL-1, CD40L, and CD80, indicating, therefore, 
that IgM-ALA has binding specificity to certain DC receptors, just 
as we observed with human T cell receptors where IgM bound to 
CD4, CD3, and CD2 but not to CD8 (39). The functional effect 
of IgM binding to certain specific co-stimulatory receptors was 
tested on LPS-activated BMDC. We show that IgM, even when 
added 2 h after LPS, inhibited LPS-induced CD40 upregulation, 
but not upregulation of CD86, PDL-1, and MHC-II of BMDC 
and downregulated basal expression of PD1 on BMDC. IgM, in 
addition, downregulated p65NF-κB activation induced by LPS 
(Figure  8D) but not by LPS +  anti-CD40 (agonistic Ab), thus 
indicating that IgM can inhibit p65NF-κB upregulation medi-
ated by TLR4 activation, but not when both TLR4 and CD40 are 
activated (4). Interestingly, IgM inhibited TLR4 activation by a 
mechanism that did not involve inhibition of LPS binding to cell 
receptors (4). However, despite downregulation by IgM of TLR4-
induced p65NF-κB, there was no decrease in IL-12 production 
or increase in IL-10 production indicating that LPS activates 
other transcription factors, besides p65NF-κB, to upregulate 
these cytokines and certain other co-stimulatory receptors that 
were not downregulated with IgM (4). In in vivo studies (to be 
presented in the next section), we show that IgM pretreatment 
of LPS-activated BMDC switches these activated BMDC to a 
regulatory phenotype possibly by a mechanism involving down-
regulation of CD40 and NF-κB.
We next did in vitro studies to test the effect of polyclonal IgM 
on Type1 NKT cells, which together with DC, have an important 
role in inducing innate inflammation, e.g., after renal reperfusion 
injury (IRI). In these studies, we used α-gal-ceramide, a glycolipid 
that is taken up by DC and presented via the CD1d receptor to 
Type 1 NKT cells, which get activated and secrete IFN-γ. This 
assay is specific for determining Type 1 NKT function as only 
Type 1 NKT, but not T effector cells, will secrete IFN-γ after 
exposure to α-gal-ceramide, which is recognized, in context of 
CD1d presentation, by the invariant TcR on Type 1 NKT cells. 
We show that physiological doses of IgM inhibits α-gal-ceramide 
TABLe 2 | In vitro effects of iqM-ALA on human and murine leukocytes.
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FiGURe 8 | In vivo infusion of polyclonal human or murine igM pretreated wT-BMDC with downregulated NF-κB protects mice from renal iRi.  
(A) There is more protection when using WT-BMDC pretreated with both IgM and LPS as evaluated by SCr. WT-BMDC were pretreated with IgM for 1 h before 
adding LPS and culturing BMDC at 37°C for 48 h. (B) LPS-activated BMDC pretreated with either mouse or human IgM are protective in renal IRI. (C) Pretreating 
48 h LPS-activated WT-BMDC with IgM for 1 h at 4°C is not protective in IRI. Fourty-eight hour IgM/LPS-pretreated WT-BMDC are non-protective in IRI after being 
irradiated (3000 Rad) or rendered apoptotic by exposure to UV light. Additionally, polyclonal IgM adsorbed with splenic leukocytes to deplete IgM-ALA clones was 
not protective in IRI. (D) Western blot depicting IgM-mediated downregulation of LPS-induced phosphorylation of p65 NF-κB in BMDC. IgM was added either 
before or after LPS activation. Figure and legend reproduced with permission from Ref. (4) Copyright 2015. The American Association of Immunologists, Inc.
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induced IFN-γ production of splenic leukocytes even when IgM 
is introduced 1  h after α-gal-ceramide (Figure  6A) (138). We 
have not defined the mechanism for the inhibitory effect of IgM 
on Type 1 NKT function.
In summary (see Table 2), the in vitro data with both human 
and murine cells would indicate that IgM-ALA regulates leuko-
cyte function by binding and downregulating certain leukocyte 
receptors (e.g., CD4 and CD2 on T cells, CD40, and CD86 on DC) 
and inducing regulatory function in DC. Importantly, IgM does 
not decrease Foxp3+ Tregs. IgM regulates leukocyte activation, 
proliferation, and chemotaxis to attenuate excess inflammation 
[Figure  6; Ref. (39)]. The marked individual variation in the 
repertoire of IgM-ALA, with specificity to the different leukocyte 
receptors, observed in both normal and disease states could 
potentially explain the differences in the vigor and character of 
inflammatory responses in different individuals exposed to the 
same inciting agent. Additionally, differences in inflammatory 
response may also be influenced by total levels of IgM-NAA or 
IgM-ALA as we observed in transplant recipients (Figure  3). 
Finally, IgM-ALA, by binding to leukocyte receptors and inhibit-
ing cell activation, can provide another mechanism to limit viral 
entry into cells and replication as we have shown with the HIV-1 
virus (Figure 2) (144).
IgM-ALA Inhibits the Innate Immune Inflammatory 
Response in Renal Ischemia Reperfusion Injury
To test the in vitro inhibitory effects of IgM-ALA on DC and NKT 
cells, we used an in vivo murine model of renal IRI (169). In this 
model, renal vessels to both kidneys are completely occluded with 
clamps for 26 or 32 min to induce either mild or severe ischemic 
15
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renal tubular injury. The kidneys are then allowed to re-perfuse 
by unclamping the blood vessels and the extent of renal injury or 
decrease in renal function is quantitated at 24 h of reperfusion by 
measuring for accumulation in the plasma of waste products (e.g., 
creatinine) that are normally only removed by the kidneys. In this 
model, the initial ischemic injury is not sufficient to impair renal 
function as quantitated by measuring plasma creatinine, but it is 
the innate inflammatory response to products released by ischemic 
renal cells (e.g., DAMPS and glycolipids) that significantly worsen 
kidney injury that leads to loss of function. In this model, DAMPS 
and glycolipids released by ischemic renal cells are taken up by 
DC and in the splenic marginal zone, DC present glycolipids in 
the context of CD1d to activate NKT cells, which rapidly release 
IFN-γ to activate innate effector cells especially granulocytes, mac-
rophages, and NK cells (169). Activated innate effectors migrate to 
the kidney, where chemokines, released by ischemic cells, enhance 
extravasation of inflammatory cells into the kidney interstitium. 
The inflammatory effector cells in the kidney interstitium cause 
further renal tubular injury with loss of kidney function that leads 
to an increase in plasma creatinine. This acute loss in kidney func-
tion is referred to as acute kidney injury (AKI).
We used two approaches to test the protective role of IgM in 
the suppression of this ischemia-induced innate inflammatory 
response. First, we performed renal IRI in B6/S4-IgMko mice 
(referred to as IgM ko) that lack circulating IgM but have nor-
mal levels of other immunoglobulins. These mice have normal 
or increased levels of Tregs, B regs, and IL-10 and their normal 
functioning B cells express membrane IgM or BcR but are unable 
to secrete IgM. Unlike their WT counterpart, we demonstrated 
that these mice are very sensitive to renal ischemia, developing 
AKI with mild ischemia (26 min clamp time) that is insufficient to 
cause AKI in their WT counterparts (Figures 9A,B). Replenishing 
IgM in the IgM ko mice with a single 240 μg dose of polyclonal 
IgM, to achieve plasma levels similar to that in their WT counter-
parts, protected these IgM ko mice from developing AKI with mild 
ischemia, thus indicating that sensitivity to ischemia in the IgM ko 
mice resulted from a lack of circulating IgM (Figures 9A,B).
In the second approach, a single dose (150 μg) of normal puri-
fied polyclonal IgM was administered intravenously to wild-type 
C57BL6 (WT-B6) mice to increase baseline circulating IgM by 
about 30–50% and to determine if increasing IgM would protect 
these WT-B6 from severe renal ischemia (32 min clamp time). 
These studies clearly indicated that increasing circulating IgM 
levels protected mice from severe renal IRI (Figure 9C). We next 
determined that this protection was mediated by IgM-ALA as 
administering similar quantity of polyclonal IgM pre-adsorbed 
with activated splenic leukocytes to remove IgM-ALA failed to 
protect these WT-B6 mice from severe renal IRI (Figure 9C).
In both approaches, physiological doses of intravenous 
polyclonal IgM mediated protection by decreasing the innate 
ischemia-induced inflammatory response. Protected kidneys 
had a very minimal inflammatory response with no or minimal 
tubular injury that could be detected on histology. Based on 
our in  vitro data, in  vivo IgM-ALA could mediate protection 
through several mechanisms, including regulation of NKT and 
DC and maintaining or enhancing Tregs, which also mediates 
protection in this model of innate inflammation (178). Our prior 
observations showing that IgM-ALA had several fold increased 
binding to splenic DC, when compared to T cells, prompted us to 
investigate the role of IgM-ALA in regulating DC in this model. 
These studies are presented in the next section.
Protection from Renal Ischemia is Mediated by IgM 
Induced Regulatory DC. Regulatory DC Require 
Tregs, B cells, Circulating IgM, and IL-10 to Mediate 
In Vivo Protection
To examine the in vivo role of IgM on DC, we used 7 to 8-day-
old cultured BMDC. In these studies, BMDC were activated ex 
vivo for 48 h with LPS with or without polyclonal IgM. Activated 
BMDC were washed and then 0.5 ×  106 BMDC were infused 
intravenously into mice 24 h before performing renal ischemia. In 
these studies, IgM + LPS-pretreated BMDC protected mice from 
ischemia induced AKI (Figures 8A) by inhibiting the increased 
generation of circulating granulocytes and inhibiting innate acti-
vated leukocytes from infiltrating the ischemic kidney [Figure 
10, Ref. (4)]. Importantly, protection with LPS-activated BMDC 
was only observed when IgM was present during the 48-h culture 
and not when IgM was added at the end of the 48 h LPS activation 
(Figure 8C), indicating therefore that regulation of BMDC by IgM 
is an active process requiring both NF-κB and CD40 downregula-
tion induced by IgM (Figure 8D). Preventing downregulation of 
NF-κB and CD40 by adding the agonistic anti-CD40 antibody to 
LPS + IgM during activation, negated the protective effect, thus 
supporting that NF-κB and CD40 downregulation are required 
to switch activated BMDC to a regulatory phenotype (4). It is 
possible that IgM by binding to CD40 induces this regulatory 
phenotype. Ex-vivo pretreatment of murine BMDC with human 
IgM was also protective in renal IRI (Figure 8B), indicating that 
the function of IgM-NAA is evolutionarily conserved among 
species.
However, since LPS activation of BMDC generates apoptotic 
cells, it is possible that protection from ischemia could be medi-
ated by complexes of IgM anti-PC and apoptotic cells, which 
when injected, regulate endogenous DC (127). Such a possibility 
seemed unlikely, as in the in vivo murine studies to demonstrate 
the anti-inflammatory role of apoptotic cells, large quantities of 
apoptotic cells (2.5 ×  107 thymocytes) were used (127), while 
in our studies, we only used 0.5 × 106 BMDC (4). However, to 
exclude the possibility of apoptotic cell-mediated protection, we 
used apoptotic BMDC by subjecting activated LPS +  IgM pre-
treated BMDC (0.5 × 106 cells) to UV irradiation. Such apoptotic 
LPS + IgM pretreated BMDC failed to protect mice from ischemia 
induced AKI, thus excluding the role of apoptotic cell/IgM 
complexes in inducing protection (Figure 8C). The latter experi-
ments indicated that IgM-ALA mediated protection by switching 
LPS-activated BMDC to a regulatory phenotype. BMDC required 
IL-10 but not IDO (indoleamine 2, 3-dioxygenase) to switch to 
a regulatory phenotype as IgM + LPS pretreatment of IL-10 ko 
BMDC, but not IDO ko BMDC, failed to protect mice from 
developing AKI after renal ischemia (4).
We hypothesize that intravenously injected regulatory 
BMDC inhibit the innate inflammatory response by entering 
the splenic marginal zone where they inhibit NKT function. 
However, in further studies, we show that injected regulatory 
FiGURe 9 | B6/S4-igMko mice are more sensitive to renal iRi when compared to their wT counterparts (wT-B6/S4). (A, B) Kidneys from B6/S4-IgMko 
mice and their WT counterparts (WT-B6/S4) were subjected to mild ischemia (26 min) and then reperfused. Data depict 24 h plasma creatinine comparing (WT-B6/
S4) WT mice with B6/S4-IgMko mice, and B6/S4-IgMko pretreated with 240 μg IgM, 24 h before ischemic injury. Histology depicts H&E staining of renal outer 
medulla after 24 h of reperfusion. (C) Polyclonal IgM, but not leukcocyte adsorbed IgM (Leu-Ads IgM), protects against renal IRI in WT-B6 mice. In these studies, 
WT-B6 mice were pretreated with equal quantities (150 μg in 0.75 ml) of IgM or Leu-Ads IgM or IgG, 24 h before subjecting the kidneys to severe ischemia (32 min). 
Kidneys were reperfused for 24 h prior to determining plasma creatinine (C). Control mice were pretreated with 0.75 ml RPMI containing 150 μg bovine albumin to 
exclude variables, such as volume/colloid, that can protect against ischemic injury. Figure and legend reproduced with permission from Ref. (138). Copyright 2012. 
The American Association of Immunologists, Inc.
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BMDC require the presence of other in  vivo suppressive 
mechanisms, such as circulating IgM, IL-10, Tregs, and B cells, 
to mediate protection (4).
In summary, IgM-ALA inhibits the ischemia-induced innate 
inflammatory response by several mechanisms, including 
 switching activated DC to a regulatory phenotype, inhibiting 
FiGURe 11 | Allograft rejection is more rapid and severe in B6/
S4-igMko mice. B6/S4-IgMko mice and their WT counterparts (WT-B6/S4) 
received cardiac allografts from B6-bm-12 donors that are only incompatible 
at the MHC-Ia locus. Graph depicts the post-transplant day when cardiac 
contractility was found to be decreased by finger palpation. Histology depicts 
Day 10 post-transplant B6-bm12 cardiac allograft histology. Figure and 
legend reproduced with permission from Ref. (138). Copyright 2012. The 
American Association of Immunologists, Inc.
FiGURe 10 | Murine igM/LPS-pretreated BMDC inhibit the inflammatory response after renal iRi. There is significantly less inflammatory cell response 20 h 
post ischemia in mice administered IgM/LPS-pretreated BMDC as determined by circulating granulocytes (CD45+, GR1+) in blood (A) and infiltrating CD45+ and 
GR1+ leukocytes in kidneys (B). CD31 is a marker for endothelial cells. 7/4 is a marker for GR1+ granulocytes. Figure and legend reproduced with permission from 
Ref. (4). Copyright 2015. The American Association of Immunologists, Inc.
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NKT cell IFN-γ production, and inhibiting chemotaxis of 
 leukocytes by binding to chemokine receptors. However, IgM-
ALA is in-effective on its own in inhibiting the ischemia-induced 
innate inflammatory response and requires the presence of other 
in vivo suppressive mechanisms, such as IL-10, Tregs and B cells. 
Conversely, these other in  vivo suppressive mechanisms, such 
as Tregs and Bregs, cannot effectively protect against ischemia 
induced innate inflammation without IgM-NAA as evidenced 
in our renal ischemia experiments using IgM ko mice that lack 
secretory IgM (Figures 9A,B).
Polyclonal IgM Inhibits Inflammation Mediated by 
Adaptive Immune Mechanisms in Allograft 
Transplantation
Because of our clinical observations (Figure 3) and the in vitro 
studies demonstrating that IgM (a) inhibited alloantigen-activated 
T cell proliferation and differentiation into Th-1 and Th-17 
independently of DC (Figure 6) and (b) could induce regulatory 
function in DC, we performed experiments aimed at determining 
whether IgM could also inhibit allograft rejection, which is an 
in vivo model of inflammation mediated by alloantigen-activated 
DC and T cells (138). Two approaches were used to test the role of 
polyclonal IgM. First, cardiac transplants were performed intra-
abdominally in B6/S4-IgM ko mice (referred to as IgM ko) or their 
WT littermates using B6-bm12 donor hearts, which are minimally 
incompatible at the MHC class II locus (Ia) with the recipient. 
In this transplant model, there is a mild chronic form of cellular 
rejection and a vasculopathy that is initiated by a T cell-mediated 
inflammatory process and cardiac graft loss (defined as loss of 
intra-abdominal cardiac pulsation) occurs at >2 months in WT 
recipients. However, in IgM ko recipients, there is a more severe 
acute cellular rejection and graft loss occurs in 2–3 weeks, which is 
significantly earlier compared with their WT-B6/S4 counterparts, 
where cardiac graft loss occurs after >2  months (Figure  11). 
Histologically, there are considerably more TH-17 cells infiltrating 
the cardiac allograft in the IgM ko recipient despite no significant 
difference in infiltrating Tregs between the groups (138). The T 
cell findings on histology mirror the in vitro studies where IgM 
inhibited naïve T cells and Foxp3+ T cells from differentiating into 
TH-17 cells without affecting levels of Tregs (Figure 6D).
In the second approach, we wanted to determine whether 
increasing circulating levels of IgM in WT-B6 mice inhibited 
the severe and rapid rejection that occurs in the setting of fully 
MHC-incompatible donor hearts (i.e., from BALB/c donors). In 
this model, rejection in WT-B6 recipients is detectable by day 5 
and graft loss occurs by 7–9 days (138). In these studies, 175 μg 
IgM was intravenously administered 24 h after ascertaining that 
cardiac surgery was successful, and the dose of IgM was repeated 
on days 3 and 5. Mice were euthanized on day 6. The data clearly 
show that IgM inhibited the severe inflammation in the cardiac 
allograft induced by rejection on day 6, as detected by H&E stain-
ing and immunofluorescence staining for neutrophils (7/4) and T 
cells (CD3). Importantly, with immunohistochemistry, this lack 
FiGURe 12 | immune response to micro-organisms.
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of leukocyte infiltration in the cardiac parenchyma of IgM-treated 
recipients was also associated with no or minimal CXCL1+ leu-
kocytes and with no or minimal fragmentation of capillaries, as 
identified by the endothelial cell marker CD31 (138).
In summary, we show that physiological doses (175  μg) of 
polyclonal IgM can subdue inflammatory responses mediated by 
an adaptive immune mechanism. Potential mechanisms include 
the following (a) a direct inhibitory effect of IgM-ALA on T effec-
tor cells, but not Tregs, possibly by binding and down-modulating 
CD3/TcR and certain specific co-stimulatory receptors, such as 
CD4 and CD2 but not CD8. As a result, T effector cells are inhib-
ited from proliferating or producing certain specific cytokines 
(e.g., TNF, IFN-γ, IL-17 but not IL-6, and chemokines) or from 
differentiating into TH-1 and TH-17 pro-inflammatory cells. 
Importantly IgM-ALA does not affect levels of Foxp3+ Tregs, but 
prevents Foxp3 + cells from differentiating into TH-17 cells under 
pro-inflammatory conditions, (b) by binding to CD40 and switch-
ing activated DC to a regulatory phenotype with downregulation 
of CD40 and p65NF-κB, and (c) by inhibiting chemotaxis. It is 
highly unlikely that IgM anti-PC could have a significant role in 
inhibiting allograft rejection in our studies as we used small doses 
of polyclonal IgM (175 μg) while 1.5–2.0 mg of a monoclonal IgM 
anti-PC (T15 idiotype) was used to inhibit an arthritis model of 
inflammation mediated by adaptive immune mechanisms (127).
Polyclonal IgM Antibodies Inhibit  
Autoimmune-Mediated Insulitis in NOD Mice
Insulitis in the NOD mouse is primarily mediated by autoimmune 
T cells but there are data to indicate that B cells are also involved. 
Depleting B cells or only B1 cells ameliorates insulitis indicating 
that some of the IgG autoantibodies detected in NOD mice may 
also be pathogenic (179–181). The role of B1 cells in generating 
pathogenic IgG autoantibodies has also been described in other 
autoimmune murine models (20, 94). Because our in vitro studies 
demonstrated that polyclonal IgM inhibited T cell proliferation 
and differentiation into Th-1 and Th-17 cells (Figures 6B–D) and 
can also counter pathogenic IgG autoantibodies (as previously 
discussed), we performed studies to determine whether IgM could 
inhibit autoimmune insulitis that results in islet cell destruction 
and diabetes mellitus (DM) in NOD mice (182). In these mice, 
the autoimmune inflammatory process begins spontaneously 
around 4–5 weeks after birth and the initial phase is character-
ized by a silent and non-destructive leukocyte infiltration of the 
perivascular and periductal regions in the pancreas as well as the 
peripheral islet regions by a heterogeneous mixture of CD4 and 
CD8 T cells, B cells, macrophages, and DC (peri-insulitis). In 
the invasive phase that begins at 8–12 weeks of age, the immune 
infiltrate enters the islet inducing beta cell destruction (insulitis). 
Significant destruction first becomes evident around 12–13 weeks 
of age with mice exhibiting overt diabetes (DM).
We wanted to determine the effect of increasing IgM levels 
on development of DM (182). NOD mice were administered bi-
weekly intra-peritoneal polyclonal IgM (50 μg/dose) beginning 
either at 5 or 11 weeks of age and ending when mice were 18 weeks 
old. At 25 weeks of age, 80% of control mice (n = 30) became 
diabetic, while 0% of mice (n = 30) treated with IgM beginning 
at 5 weeks developed DM. Importantly, only 20% of pre-diabetic 
mice (n = 20) treated with IgM beginning at 11 weeks of age devel-
oped DM at 25 weeks of age. This latter observation is particularly 
notable as prior studies using co-stimulatory blockade failed to 
prevent DM in this murine model. At 18–25  weeks of age the 
pancreas revealed no or minimal insulitis in NOD mice treated 
with IgM beginning at 5 weeks of age. Other investigators using 
monoclonal polyreactive natural IgM in the neonatal period have 
also obtained similar results (183, 184).
In summary, these studies indicate that polyclonal IgM inhibits 
insulitis via several potential mechanisms, including inhibition of 
autoimmune T effectors and possibly countering IgG autoanti-
bodies via anti-idiotypic mechanisms and by inhibiting the B cells 
that produce them. Additionally, IgM by switching activated DC 
to a regulatory phenotype and maintaining Tregs could enhance 
this protective effect.
CONCLUSiON
Figures 12 and 13 summarize our concepts of the inter- relationship 
between pathogens and natural antibodies. In both murine and 
human models, the evidence shows that these polyreactive and 
low-affinity binding IgM-NAA function under physiological 
conditions to (i) provide a first line of defense against invading 
organisms, (ii) protect the host from autoimmune inflammation 
mediated by autoimmune B and T cells that have escaped tolerance 
mechanisms, (iii) protect the host from endogenous oxidized neo-
determinants and other neo-antigens that are unmasked during 
tissue damage, and (iv) regulate excess inflammation, mediated 
by both innate and adaptive immune mechanisms. Even though 
the full repertoire of IgM-NAA develop during the first few years 
of life, both their levels and repertoire differ in healthy individuals 
as well as in disease and could contribute to the varying inflam-
matory response, for example, after an infection or alloantigen 
exposure (see Figures  2 and  5). We hypothesize that high 
FiGURe 13 | Pathogen-induced natural igM protects host from pathogen-mediated inflammation and autoimmunity.
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protective levels of IgM-NAA are maintained by infections that 
have been shown to increase IgM-NAA, especially IgM-ALA and 
anti-PC [reviewed in Ref. (31, 39, 148)]. Such a hypothesis could 
explain the significantly low incidence of autoimmune disorders, 
such as SLE or sarcoidosis in rural parts of Africa where malaria 
and other infections are endemic (185–187). We have shown that 
IgM-ALA increases in active sarcoidosis (188). There are other 
suppressive mechanisms (e.g., Tregs, B regs, IL-10, TGF-β) that 
regulate inflammation and based on the different animal models 
of inflammation, it would appear that IgM-NAA have a more 
prominent role in regulating inflammation that involves patho-
genic IgG autoantibodies, macrophages, and NKT cells. However, 
we show that IgM-NAA require Tregs, B cells, and IL-10 to be 
fully effective in controlling inflammation (4). Conversely, our 
studies and that of others, using mice deficient in IgM secretion, 
would also indicate that Tregs and Bregs also require IgM-NAA 
to effectively control inflammation (39, 119, 120). Finally, it may 
be easier to develop a vaccine to increase IgM-NAA especially if 
we understand how diverse infectious agents increase IgM-ALA. 
Studies are also needed to determine if prolonged high IgM-NAA 
levels can induce excess immunosuppression. One could also use 
enriched IgM intravenous preparations to acutely treat patients 
with uncontrolled inflammation. Cell therapy, especially with 
IgM pretreated DC, could provide an alternative approach requir-
ing minimal quantities of IgM to prevent ischemic acute renal 
failure (e.g., in high-risk patients undergoing cardiac surgery) or 
delayed graft function after renal transplantation (4).
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